Related Experiment Video
Updated: May 11, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.4K
TACE With Doxorubicin-Induced Cardiotoxicity
Theo Doyon1, Corrado De Marco1, Philippe Willems1
1University of Montreal, Montreal, Quebec, Canada.
JACC. Case Reports
|April 18, 2025
Summary
Conventional transarterial chemoembolization (TACE) with doxorubicin can cause severe cardiotoxicity in hepatocellular carcinoma patients. Drug-eluting beads-TACE offers a safer alternative, preventing serious complications like transplant list removal.
Area of Science:
- Oncology
- Cardiology
- Interventional Radiology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer.
- Transarterial chemoembolization (TACE) is a standard HCC treatment.
- Doxorubicin is a potent chemotherapeutic agent used in TACE, known for cardiotoxicity.
Observation:
- A 58-year-old male with HCC received five conventional TACE treatments using doxorubicin.
- The patient developed severe cardiotoxicity following the treatments.
- This cardiotoxicity led to his removal from the liver transplant waitlist.
Findings:
- Conventional TACE with doxorubicin can lead to severe, preventable cardiotoxicity.
- Drug-eluting beads-TACE demonstrates comparable efficacy with improved safety profiles.
- Early recognition and alternative treatment strategies are crucial for managing HCC patients.
Implications:
- This case highlights the significant risk of cardiotoxicity with conventional TACE, underscoring the need for increased awareness.
- Drug-eluting beads-TACE should be considered the preferred treatment modality, especially for vulnerable patients.
- Preventing doxorubicin-induced cardiotoxicity can improve patient outcomes and eligibility for liver transplantation.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
405
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
405
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
808
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
808
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.0K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
640
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
640
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
680
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
680